LIPOTYPE
Desconocido
UNLOOC: Unlocking data content of Organ On Chips
The launch of a novel drug to the market is preceded by clinical testing and validation both on animal in vitro and in vivo models. Animal m...
2024-06-28 - 2027-04-30 | Financiado
2024-06-28 - 2027-04-30 | Financiado
Long Covid: Decision support for prediction and management of Long Covid Syndrome (LCS)
LIPOTYPE
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-DISEASE-04
We will develop tools and knowledge to support physicians in accurately managing Long COVID syndrome (LCS) which has a significant impact on...
2022-05-23 - 2026-05-31 | Financiado
2022-05-23 - 2026-05-31 | Financiado
SOPHIA: Stratification of Obesity Phenotypes to Optimize Future Therapy
LIPOTYPE
participó en un
H2020:
H2020-JTI-IMI2-2019-17-two-stage
SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of sel...
2020-05-26 - 2025-05-31 | Financiado
2020-05-26 - 2025-05-31 | Financiado
ISLET: Advancing Innovative Stem Cell based Therapy for Diabetes in Europe
LIPOTYPE
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Type 1 diabetes (T1D) is one of the main health challenges, with 6 million European citizens affected. Today, T1D accounts for a severe econ...
2019-12-12 - 2025-02-28 | Financiado
2019-12-12 - 2025-02-28 | Financiado
REMEDIA: Impact of exposome on the course of lung diseases
LIPOTYPE
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are two very debilitating non-communicable diseases that are of partic...
2019-12-06 - 2024-12-31 | Financiado
2019-12-06 - 2024-12-31 | Financiado
BEAt-DKD: Biomarker Enterprise to Attack DKD Sofia ref. 115974
LIPOTYPE
participó en un
H2020:
H2020-JTI-IMI2-2015-05-two-stage
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached e...
2016-12-20 - 2023-08-31 | Financiado
2016-12-20 - 2023-08-31 | Financiado
LysoMod: Genetic and Small Molecule Modifiers of Lysosomal Function
LIPOTYPE
participó en un
H2020:
H2020-MSCA-RISE-2016
LysoMod will innovate in the area of personalized medicine for disorders linked to lysosomal dysfunction. This will be achieved by implement...
2016-10-28 - 2022-08-31 | Financiado
2016-10-28 - 2022-08-31 | Financiado
RHAPSODY: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification S...
LIPOTYPE
participó en un
H2020:
H2020-JTI-IMI2-2015-03-two-stage
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, info...
2016-06-07 - 2021-09-30 | Financiado
2016-06-07 - 2021-09-30 | Financiado
* No se disponen de datos de la empresa actual.